The Generics Bulletin Podcast: Discussing Sandoz’s Strategy As It Prepares For A Biosimilars Boom
Sandoz’s Bio100 strategy sets out the firm’s ambition to have more than 100 biosimilars in its portfolio by 2040 and more than double sales from 2025 to 2035. Fresh from the announcement at the London Stock Exchange, Generics Bulletin editors Dave Wallace and Dean Rudge discusses the key aspects.
Generics Bulletin - September 9, 2026

EU Safety Review Will Shape Fate Of Two Fragrance Constituents
At the request of the European Commission, the Scientific Committee on Consumer Safety will take a look at the safety of cuminaldehyde and p-cymene as fragrance constituents.
HBW Insight - September 9, 2026

FDA Opens 510(k) Pathway for Eight Device Types
The latest batch of FDA classification orders includes foam that protects reproductive organs during radiation therapy, an ENT robotic platform, and an implant to treat urinary incontinence.
Medtech Insight - September 9, 2026

‘Uncertainty, Unpredictability’ Holding Back Rx-To-OTC Switch In US, But ACNU Could Be Game-Changer
Rx-to-OTC switch is stalling in the US, with regulatory unpredictability discouraging manufacturers and holding back the plans of companies like Haleon and Opella. Could the new ACNU pathway be the mechanism to finally open up new OTC categories?
HBW Insight - September 9, 2026

Kura Spins Out Caspian With $50m To Test Menin Inhibition In Diabetes
Kura Oncology will keep its focus on menin inhibition in cancer as it spins out Caspian Therapeutics to develop KO-7246 in chronic metabolic diseases, including type 1 and 2 diabetes.
Scrip - September 9, 2026

Bonus Podcast: ZS On How Patients Are Changing Their Own Journeys With AI
Patients are increasingly empowered by the ability to use AI to control their healthcare journeys. A landmark three-country survey by ZS noted how this trend was becoming generalized. ZS’ Jon Roffman and Bhargav Mantha highlight how traditional healthtech and pharma industries must react.
In Vivo - September 9, 2026

Dealmaking Quarterly Statistics, Q2 2026
During Q2, biopharma merger and acquisition deal value reached $92.6bn and drew in $82.3bn in potential deal value from alliances. Device company M&A values reached $4.3bn, while in vitro diagnostics and research tools players’ M&A activity totaled $14.5bn.
In Vivo - September 9, 2026

Hydrocortisone Comparison Won Germany’s Switch Committee Over To OTC Prednisolone
An established self-medication track record with comparable products was what carried prednisolone, digitoxin and olopatadine through Germany's switch committee in July, according to recently published full minutes.
HBW Insight - September 9, 2026

Updated US FDA Therapeutic Equivalence Guidance Allows Faster 505(b)(2) Rating Requests
505(b)(2) sponsors now may request a therapeutic equivalence rating when their product's inactive ingredients differ from the reference listed drug.
Generics Bulletin - September 9, 2026

Rivastigmine Rises Dominate UK Increases In August
Multiple presentations of rivastigmine capsules saw their UK trade prices more than double in August, according to the latest figures from WaveData.
Generics Bulletin - September 9, 2026

After Some Big Flops, What’s Next In Cardiovascular Outcomes Studies?
Novo Nordisk and Novartis have both been dealt big blows by the recent failure of their major cardiovascular outcome studies. More CVOT readouts for novel agents are on the way but the bar for success keeps being raised.
Scrip - September 9, 2026

Priothera Seeks Partner As Mocravimod Advances In Phase III Leukemia Trial
The timelines for the MO-TRANS trial of the sphingosine 1 phosphate receptor modulator have been pushed back as the number of patients enrolled increased significantly but that ‘puts us in the strongest position to generate robust Phase III data,’ CEO Florent Gros tells Scrip.
Scrip - September 9, 2026

Boston Scientific Says Cyberattack Makes 2026 Guidance ‘Unlikely’ To Be Met
The medical device maker says an Aug. 25 cyberattack makes 2026 guidance “unlikely” to be met, sending shares down 5.9%, in a year already marked by a Watchman slowdown.
Medtech Insight - September 9, 2026

Evommune Scraps Second EVO756 Program But Presses On In Migraine
After two Phase IIb setbacks for EVO756, Evommune turns its AD focus to EVO301 while advancing the MRGPRX2 antagonist in migraine.
Scrip - September 9, 2026

Structure’s Oral Amylin Shows Early Promise In First Human Test
Structure's oral amylin ACCG-2671 drove up to 3.3% weight loss in its first human trial, but dose-related nausea and a modest headline number sent shares down 14.7%.
Scrip - September 9, 2026

ChrysCapital’s NIL Bags Minipress XL, Steps Into Ophthalmology In Rapid Deal Burst
ChrysCapital controlled Novartis India Ltd, which is being renamed as Evonile Pharma, seals back-to-back deals, picking up Pfizer's Minipress XL brand and locking in distribution rights for Novartis's ranibizumab and brolucizumab in India.
Scrip - September 9, 2026

The Company Betting It Can Simulate A Human Body
Deep Origin claims that in silico models can one day replace animal testing, and has published wet lab results to argue the models already work. It has also publicly committed to never developing a pipeline.
In Vivo - September 9, 2026

UpFront’s Finger-Prick Stroke Blood Test Gets First-Of-Its-Kind CE Mark
Company says combination of novel biomarkers can detect large vessel occlusion stroke in under 10 minutes.
Medtech Insight - September 9, 2026